VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.
https://www.globenewswire.com/news-release/2021/02/01/2167200/0/en/Algernon-Pharmaceuticals-Launches-Stroke-Treatment-Clinical-Research-Program-with-Psychedelic-Drug-DMT-The-Spirit-Molecule.html